Deep Deal Research

Every company arrives IC research-complete.

Founder background, market sizing, competitor map, regulatory landscape — attached before the meeting. Analysts spend hours on judgement, not weeks on tab-opening.

The problem

Deep research doesn’t scale.

Done by hand, the full work-up on a single company eats the better part of an analyst-week. That math forces a brutal triage: only the deals with the loudest intros ever get it.

Founder research: hours of LinkedIn tabs, never the same way twice.
TAM / SAM / SOM: weeks of manual sizing or an expensive consultant.
Competitive landscape: inconsistent from one analyst to the next.
Regulatory: usually skipped at sourcing, then surfaces too late.

Everything in the quiet tail advances on a thin read — or never advances at all.

Today’s status quo

Four different tools — and none of them stack.

Founders, today

LinkedIn Sales Navigator, Apollo, Clay, scattered founder graphs.

Market sizing, today

Gartner, Forrester, Statista, and manual spreadsheets.

Competitors, today

PitchBook comps, SimilarWeb, G2, hand-drawn maps.

Regulatory, today

Outside counsel and legal databases — usually skipped entirely.

Each tool solves one flavor. None apply your thesis. None produce cross-deal comparable output.

Stage 3 · Detailed Scope

One evidence corpus. Structured research. A source for every claim.

Once Stage 1 has screened your market, every surviving company goes through Detailed Scope — the same structure for each one, with a source behind every line. Stage 1 is live today; the deeper scopes are rolling out.

Evidence corpus
Website content, founder enrichment, and deep research gathered once per company.
Research phases
Founders, market, competition, investors, and risk — each feeding one growing dossier.
Structured output
The same fields for every company — comparable across your whole shortlist.

Founders & team

Per founder: track record, prior companies, and exit signal — plus founder–market fit and an overall read on team quality.

Market & sizing

TAM / SAM / SOM with the assumptions and sources behind them, and an honest read on how crowded the market is.

Problem, solution & moat

How acute the problem is, how far the product has actually got, and how defensible the unfair advantage really is.

Competitive landscape

The closest competitors — and what actually differentiates this company from them.

Investors & funding

Who is backing the company and the round history — a read on investor quality, not just a list of logos.

Risk & regulatory

Legal and regulatory risk signals surfaced from the evidence, each traced back to a source.

ProteinForge
Alternative-protein ingredient platform · fictional sample
Stage 1 passed
CEO — Dr. Lena HoffmannQualification: High
Ex-Head of R&D at a top-5 ingredients group; 11 years scaling fermentation.
source: LinkedIn
CTO — Marco ReyesExit signal: High
PhD in synthetic biology; two prior exits in industrial biotech.
source: Crunchbase
Team qualityStrong
Senior, domain-deep bench across fermentation, food science, and GTM.
source: Enriched corpus
Founder–market fit
Both founders spent careers in the exact category they now build for.
source: LinkedIn
Why it wins

Cross-deal comparable. Focused. Audit-grade.

Same format every time

Apples-to-apples across your whole shortlist — not a different write-up per analyst.

Spent only on survivors

Detailed Scope runs only on companies your thesis has already advanced — never on dead deals.

Every claim has a source

Each line traces back to where it came from, graded by how well it’s sourced. IC questions get answered, not deferred.

Bring a deal. Get a dossier.

Send us a Stage 1 survivor from your pipeline. We’ll run Detailed Scope and walk you through the output.